Date:12/8/2009

ne http://www.europeanurology.com/current-issue) suggest that a PSA cut off level of 3ng/ml combined with an individual risk assessment would reduce biopsies by 33%. The majority of cancers potentially missed would be indolent, so there would be no benefit from active treatment. Increasing the PSA cut-off level from 3 to 4 ng/ml may save a similar number of biopsies, but will miss more clinically significant cancers.

*NEJM, March 2009

**European Urology, October 2009

SOURCE European Randomized Study of Screening for Prostate Cancer (ERSPC)

'/>"/>

SOURCE European Randomized Study of Screening for Prostate Cancer (ERSPC) Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. Kline Study: Better Brushing Habits Boost European Oral Care Sales
2. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
3. Murad Boosts Skin Immunity With the New Murad(R) Professional Line
4. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
5. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
6. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
7. New Scandinavian collaboration boosts nanotech development
8. Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
9. Three Steps to Boost Asymchems Investment in China
10. Advanced Energy Consortium will develop micro and nanosensors to boost energy production
11. Boost for Malaria Vaccine Development by Combining Strengths of Dutch and American Researchers